FDA grants three FTDs for Allogene’s ALLO-329 - BioTuesdays

FDA grants three FTDs for Allogene’s ALLO-329 - BioTuesdays

Allogene Therapeutics (NASDAQ:ALLO) announced that the FDA has granted three fast track designations (FTDs) for its ALLO-329, a next-generation dual-target CD19/CD70 allogeneic CAR T for the treatment of lupus, myositis, and scleroderma. According to Allogene, the FDA designations follow recent investigational new drug (IND) application clearance for the RESOLUTION Basket Study of ALLO-329 in rheumatology. The launch of its Phase 1 REVOLUTION tr…

ALLO-329 gets FDA fast track designation for diffuse scleroderma

The FDA has granted fast track designation to the experimental cell therapy ALLO-329 to treat diffuse scleroderma and two other conditions.